Spectral Med Inc has seen notable movements in its stock this week, reflecting investor interest in its recent developments.
This week, Spectral Med Inc (EDT.TO) experienced a modest increase of 5.26%, closing at C$1.40, despite a slight decline of 1.41% on the last trading day. The stock has been buoyed by recent headlines surrounding its regulatory efforts and financial updates, which may influence investor sentiment moving forward.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$416.65M
52W high
$1.76
52W low
$0.77
1W change
+5.26%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 125.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+125.0% Upside
Current Price
C$1.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
24.1%
Annualized
90-Day Vol
34.0%
Annualized
Trend (90d)
+9.1%
Annualized drift
90d Mean
C$1.45
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.42 | C$1.30 โ C$1.54 |
| 60 trading days | C$1.43 | C$1.27 โ C$1.61 |
| 90 trading days | C$1.45 | C$1.25 โ C$1.67 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Spectral Med's ongoing regulatory developments and financial performance, as these factors could significantly impact the company's future in the healthcare sector.
5.26% Weekly Gain
The stock has shown resilience with a weekly gain of 5.26%, reflecting positive investor sentiment amid ongoing regulatory efforts.
Bull case
The company's recent submission of a Premarket Approval application for PMX to the U.S. FDA is a crucial step in its commercialization efforts. This move could open up significant market opportunities for Spectral Med.
Bear case
On the downside, Spectral Med's financials show some challenges, including a negative return on equity and a profit margin of 0.0%. These issues may raise concerns about the company's long-term viability and financial health.
Recent Price Action
Spectral Med Inc's stock closed at C$1.40, reflecting a 1.41% decline on the last trading day, but a notable increase of 5.26% over the past week. This performance comes against the backdrop of recent developments concerning the company's regulatory applications and corporate updates.
Catalysts Driving Investor Interest
Recent headlines have highlighted key milestones for Spectral Med, including the submission of its Premarket Approval (PMA) application for PMX to the U.S. FDA. This is seen as a significant step in the company's efforts to bring its endotoxin removal therapy to the U.S. market. Additionally, the company's financial results for the first quarter of 2026 indicated progress in regulatory and commercial readiness, which may further bolster investor confidence.
Technical Picture
From a technical standpoint, Spectral Med's stock is trading slightly above its 50-day moving average of C$1.38 and its 200-day moving average of C$1.37, indicating a positive short-term trend. The stock has a 52-week range of C$0.77 to C$1.76, currently sitting at approximately 64% of that range. The low beta of 0.21 suggests that the stock is less volatile compared to the broader market. However, volume has been relatively low, with the latest trading volume at 20,425 shares, which is only 41% of the 20-day average volume of 49,325 shares.
Insider Activity
There are no recent reports of insider activity for Spectral Med Inc, indicating that there have been no significant purchases or sales by company executives or major shareholders that could provide additional insights into the company's outlook.
Advertisement
